Catechin attenuates behavioral neurotoxicity induced by 6-OHDA in rats

Pharmacology Biochemistry and Behavior

Volumn 110, Issue , 2013, Pages 1-7

  Teixeira, M D A ^a   Souza, C M ^a   Menezes, A P F ^a   Carmo, M R S ^a   Fonteles, A A ^a   Gurgel, J P ^a   Lima, F A V ^a   Viana, G S B ^a   Andrade, G M ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

6 OHDA; Catechin; GSH; Memory; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ANTIOXIDANT; APOMORPHINE; CATECHIN; DOPAMINE; GLUTATHIONE; MONOAMINE; NEUROPROTECTIVE AGENT; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; AVERSIVE BEHAVIOR; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MESENCEPHALON; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PREMEDICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; WORKING MEMORY;

ANIMALIA; RATTUS;

6-OHDA; CATECHIN; GSH; MEMORY; PARKINSON'S DISEASE;

ANIMALS; BEHAVIOR, ANIMAL; CATECHIN; CORPUS STRIATUM; GLUTATHIONE; MALE; MEMORY; MESENCEPHALON; OXIDOPAMINE; RATS; RATS, WISTAR; TYROSINE 3-MONOOXYGENASE;

EID: 84878711586     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.05.012     Document Type: Article

References (67)

1. Anglade P, Vyas S, Hirsch EC, Agid Y. Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 1997;12:603-10. (Pubitemid 27314689)
2. Babu PV, Sabitha KE, Shyamaladevi CS. Therapeutic effect of green tea extract on oxidative stress in aorta and heart of streptozotocin diabetic rats. Chem Biol Interact 2006;162: 114-20. (Pubitemid 44189959)
3. Bellissimo MI, Kouzmine I, Ferro MM, de Oliveira BH, Canteras NS, Da Cunha C. Is the unilateral lesion of the left substantia nigra pars compacta sufficient to induce working memory impairment in rats? Neurobiol Learn Mem 2004;82:150-8. (Pubitemid 39070260)
4. Braga R, Kouzmine I, Canteras NS, Da Cunha C. Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats. Exp Neurol 2005;192: 134-41. (Pubitemid 40208546)
5. Broadhurst PL. Determinants of emotionality in the rat: in situational factors. Br J Psychol 1957;48:1-12.
6. Brown RG, Marsden CD. How common is dementia in Parkinson's disease? Lancet 1984;2:1262-5. (Pubitemid 15217727)
7. Chan P, Cheng JT, Tsai JC, Lien GS, Chen FC, Kao PF, et al. Effect of catechin on the activity and gene expression of superoxide dismutase in cultured rat brain astrocytes. Neurosci Lett 2002;328:281-4. (Pubitemid 34876666)
8. Chase TN, Oh JD, Blanchet PJ. Neostriatal mechanisms in Parkinson's disease. Neurology 1998;51:S30-5. (Pubitemid 28397141)
9. Chen C, Yu R, Owuor ED, Kong AN. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res 2000;23: 605-12.
10. Da Cunha C, Wietzikoski S, Wietzikoski EC, Silva MH, Chandler Jr J, Ferro MM, et al. Pre-training to find a hidden platform in the Morris water maze can compensate for a deficit to find a cued platform in a rat model of Parkinson's disease. Neurobiol Learn Mem 2007;87:451-63. (Pubitemid 46483127)
11. DeNoble VJ, Repetti SJ, Gelpke LW, Wood LM, Keim KL. Vinpocetine: nootropic effects on scopolamine-induced and hypoxia-induced retrieval deficits of a step-through passive avoidance response in rats. Pharmacol Biochem Behav 1986;24:1123-8. (Pubitemid 16074798)
12. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997;244:2-8. (Pubitemid 26413891)
13. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha CJ. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 2005;148:78-87. (Pubitemid 41423461)
14. Gassen M, Youdim MB. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol Toxicol 1997;80: 159-66. (Pubitemid 27168862)
15. Georgiev V, Kambourova T. Behavioural effects of angiotensin II in the mouse following MPTP administration. Gen Pharmacol 1991;22:625-30.
16. Gevaerd MS, Miyoshi E, Silveira R, Canteras NS, Takahashi RN, Da Cunha C. L-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats. Int J Neuropsychopharmacol 2001;4:361-70. (Pubitemid 33151679)
17. Guo Q, Zhao B, Li M, Shen S, Xin W. Studies on protectivemechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochem Biophys Acta 1996;1304:210-22. (Pubitemid 26426992)
18. Haque AM, Hashimoto M, Katakura M, Tanabe Y, Hara Y, Shido O. Long-term administration of green tea catechins improves spatial cognition learning ability in rats. J Nutr 2006;136:1043-7.
19. Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004;110:118-23. (Pubitemid 39044049)
20. Jenner P. Preventing and controlling dyskinesia in Parkinson's disease: a view of current knowledge and future opportunities. Mov Disord 2008;3(Suppl. 3):S585-98.
21. Jeong HS, Jang S, Jang MJ, Lee SG, Kim TS, Tag Heo, et al. Effects of (-)-epigallocatechin-3-gallate on the activity of substantia nigra dopaminergic neurons. Brain Res 2007;1130:114-8. (Pubitemid 46075112)
22. Karlsen KH, Larsen JP, Tandberg E, Maland JG. Quality of life measurements in patients with Parkinson's disease: a community-based study. Eur J Neurol 1998;5:443-50. (Pubitemid 28469997)
23. Kim CY, Lee C, Park GH, Jang JH. Neuroprotective effect of epigallocatechin-3-gallate against beta-amyloid-induced oxidative and nitrosative cell death via augmentation of antioxidant defense capacity. Arch Pharm Res 2009;32:869-81.
24. Knowlton BJ, Mangels JA, Squire LR. A neostriatal habit learning system in humans. Science 1996;273:1399-402. (Pubitemid 26296530)
25. Koh SH, Kim SH, Kwon H, Park Y, Kim KS, Song CW, et al. Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radicalstress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Brain Res Mol Brain Res 2003;118:72-81. (Pubitemid 37238989)
26. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 1992;107(2-3):394-404.
27. Levites Y, Weinreb O, Maor G, Youdim MBH, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridineinduced dopaminergic neurodegeneration. J Neurochem 2001;78:1073-82. (Pubitemid 32823156)
28. Levites Y, Amit T, Mandel S, Youdim MB. Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J 2003;17: 952-4.
29. Li Q, Zhao HF, Zhang ZF, Liu ZG, Pei XR, Wang JB, et al. Long-term green tea catechin administration prevents spatial learning and memory impairment in senescenceaccelerated mouse prone-8 mice by decreasing Abeta1-42 oligomers and upregulating synaptic plasticity-related proteins in the hippocampus. Neuroscience 2009a;163:741-9.
30. Li Q, Zhao HF, Zhang ZF, Liu ZG, Pei XR, Wang JB, et al. Long-term administration of green tea catechins prevents age-related spatial learning and memory decline in C57BL/6J mice by regulating hippocampal cyclic amp-response element binding protein signaling cascade. Neuroscience 2009b;159:1208-25.
31. Lindner MD, Cain CK, Plone MA, Frydel BR, Blaney TJ, Emerich DF, et al. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav Brain Res 1999;102:1-16. (Pubitemid 29314564)
32. Mandel SA, Amit T, Kalfon L, Reznichenko L, Youdim MB. Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins. J Nutr 2008;138:1578S-83S.
33. Nakagawa K, Miyazawa TJ. Absorption and distribution of tea catechin, (-)-epigallocatechin-3-gallate, in the rat. J Nutr Sci Vitaminol 1997;43:679-84. (Pubitemid 28045726)
34. Nobre-Júnior HV, Cunha GM, Maia FD, Oliveira RA, Moraes MO, Rao VS. Catechin attenuates 6-hydroxydopamine (6-OHDA)-induced cell death in primary cultures of mesencephalic cells. Comp Biochem Physiol C Toxicol Pharmacol 2003;136:175-80. (Pubitemid 37237552)
35. Owen AM, Doyon J, Dagher A, Sadikot A, Evans AC. Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions. Brain 1998;121:949-65. (Pubitemid 28220900)
36. Packard MG, McGaugh JL. Double dissociation of fornix and caudate nucleus lesions on acquisition of two water maze tasks: further evidence for multiple memory systems. Behav Neurosci 1992;106(3):439-46.
37. Packard MG, Hirsh R, White NM. Differential effects of fornix and caudate nucleus lesions on two radial maze tasks: evidence for multiple memory systems. J Neurosci 1989;9(5):1465-72. (Pubitemid 19146244)
38. Papapetropoulos S, Ellul J, Polychronopoulos P, Chroni E. A registry-based, case-control investigation of Parkinson's disease with and without cognitive impairment. Eur J Neurol 2004;11:347-51. (Pubitemid 38903570)
39. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. London: Academic Press; 1986.
40. Perry JC, Da Cunha C, Anselmo-Franci J, Andreatini R, Miyoshi E, Tufik S, et al. Behavioural and neurochemical effects of phosphatidylserine in MPTP lesion of the substantia nigra of rats. Eur J Pharmacol 2004;484:225-33. (Pubitemid 38117214)
41. Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN. The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol 2006;202:391-403. (Pubitemid 44692682)
42. Pu F, Mishima K, Irie K, Motohashi K, Tanaka Y, Orito K, et al. Neuroprotective effects of quercetin and rutin on spatial memory impairment in an 8-arm radial maze task and neuronal death induced by repeated cerebral ischemia in rats. J Pharmacol Sci 2007;104:329-34. (Pubitemid 47378420)
43. Reksidler AB, Lima MM, Zanata SM, Machado HB, da Cunha C, Andreatini R, et al. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 2007;560:163-75. (Pubitemid 46341312)
44. Renno WM, Al-Maghrebi M, Al-Banaw A. (-)-Epigallocatechin-3-gallate (EGCG) attenuates functional deficits and morphological alterations by diminishing apoptotic gene overexpression in skeletal muscles after sciatic nerve crush injury. Naunyn-Schmiedeberg's Arch Pharmacol 2012;385:807-22.
45. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F] fluorodopa positron emission tomographic study. Arch Neurol 2000;57:470-5. (Pubitemid 30212118)
46. Sarter M, Bodewitz G, Stephens DN. Attenuation of scopolamine-induced impairment of spontaneous alternation behavior by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology 1988;94:491-5. (Pubitemid 18087398)
47. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004;318:215-24. (Pubitemid 39366054)
48. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000;15: 112-1118.
49. Schroeder EK, Kelsey NA, Doyle J, Breed E, Bouchard RJ, Loucks FA. Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. Antioxid Redox Signal 2009;11:469-80.
50. Schwarting RKW, Huston JP. The unilateral 6 hydroxydopamine lesionmodel in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996;50:275-331. (Pubitemid 26412599)
51. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968;25:192-205.
52. Skrzydlewska E, Ostrowska J, Stankiewicz A, Farbiszewski R. Green tea as a potent antioxidant in alcohol intoxication. Addict Biol 2002a;7:307-14. (Pubitemid 34848418)
53. Skrzydlewska E, Ostrowska J, Farbiszewski R, Michalak K. Protective effect of green tea against lipid peroxidation in the rat liver, blood serum and the brain. Phytomedicine 2002b;9:232-8. (Pubitemid 34475556)
54. Soto-Otero R, Méndez-Alvarez E, Hermida-Ameijeiras A, Muñoz-Patiño AM, Labandeira-Garcia JL. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem 2000;74:1605-12. (Pubitemid 30163982)
55. Sutherland BA, Shaw OM, Clarkson AN, Jackson DN, Sammut IA, Appleton I. Neuroprotective effects of (-)-epigallocatechin gallate following hypoxia-ischemiainduced brain damage: novel mechanisms of action. FASEB J 2005;19:258-60. (Pubitemid 40189274)
56. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 2003;53:S61-70.
57. Tompkins MM, Basgall EJ, Zamrini E, Hill WD. Apoptotic-like changes in Lewy-bodyassociated disorders and normal aging in substantia nigral neurons. Am J Pathol 1997;150:119-31. (Pubitemid 27027103)
58. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 1971;367: 69-93.
59. Vale S. Current management of the cognitive dysfunction in Parkinson's disease: how far have we come? Exp Biol Med 2008;233:941-51.
60. van Acker SA, van den Berg DJ, Tromp MN, Griffioen DH, van Bennekom WP, van der Vijgh WJ, et al. Structural aspects of antioxidant activity of flavonoids. Free Radic Biol Med 1996;20:331-42. (Pubitemid 26077855)
61. Warren NM, Piggott MA, Perry EK, Burn DJ. Cholinergic systems in progressive supranuclear palsy. Brain 2005;128:239-49. (Pubitemid 40222593)
62. White NM, McDonald RJ. Multiple parallel memory systems in the brain of the rat. Neurobiol Learn Mem 2002;77(2):125-84. (Pubitemid 34971650)
63. Williams RJ, Spencer JPE. Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease. Free Radic Biol Med 2012;52:35-45.
64. Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 2006;20:477-505. (Pubitemid 43830737)
65. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
66. Youdim KA, Spencer JP, Schroeter H, Rice-Evans C. Dietary flavonoids as potential neuroprotectants. Biol Chem 2002;383:503-19. (Pubitemid 34506287)
67. Yu S, Zheng W, Xin N, Chi ZH, Wang NQ, Nie YX, et al. Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. Rejuvenation Res 2010;13:55-64.